Hematology Hospital of the Chinese Academy of Medical Sciences — Tianjin

Public research footprint of Hematology Hospital of the Chinese Academy of Medical Sciences, compiled from the ClinicalTrials.gov public registry.

Registered studies

Active

Recruiting now

Completed

Most-studied conditions

Acute Myeloid Leukemia · Relapsed B-cell Acute Lymphoblastic Leukemia · Recurrent Diffuse Large B-Cell Lymphoma · Lymphoma, Small Lymphocytic

Recently updated registry entries

NCT07218341 — A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic… (Recruiting)
NCT06319456 — A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy… (Recruiting)
NCT06721013 — A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Hematology Hospital of the Chinese Academy of Medical Sciences?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 07, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.